Day: June 21, 2021

Akoustis Signs First Foundry Agreement with 5G Mobile RF Front-End Customer

Written by Customer Service on June 21, 2021. Posted in Public Companies.

Akoustis to Produce Filters for 5G Mobile Smartphones and Other Devices Production Ramp Expected in 2nd Half of Calendar 2022Charlotte, N.C., June 21, 2021 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has signed a foundry agreement with a mobile RF front-end customer for the manufacture of XBAW® filters for 5G mobile handsets and other wireless devices. Akoustis will manufacture the new high frequency RF filter using its patented and proprietary XBAW® process at its fab in Canandaigua, NY. The foundry agreement was reached after the customer evaluated initial filter samples that Akoustis delivered in the March 2021...

ROSINBOMB™ Featured in Exclusive Interview With Blunt Business on Cannabis Radio

Written by Customer Service on June 21, 2021. Posted in Public Companies.

Industry Leading Developer of Solventless Extraction Technology and Products Discuss Their Continued Commitment Empowering the Development of High-Quality Safe Extracts and Their On-Going Collaboration With Tommy RENO, Nev., June 21, 2021 (GLOBE NEWSWIRE) — ROSINBOMB (OTC:ROSN), industry leading developer and manufacturer of the highly acclaimed ROSINBOMB line of solventless extraction presses was the featured company on the Blunt Business Podcast on Cannabis Radio. The company discussed their exclusive collaboration with Industry Icon Tommy Chong, which offers consumers a custom Tommy-art skinned Rosinbomb Rocket as well as their continued commitment to enabling consumers and processors to craft their own high quality, solventless and safe concentrates. Rosinbomb Founder and President Ryan Mayer and C.E.O. Fred Angelopoulos were...

Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

Written by Customer Service on June 21, 2021. Posted in Public Companies.

Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development Condition Afflicts More Than 30 Percent of Patients Post Infection with SARS-CoV-2, the Virus that Causes COVID-19 Pre-IND Meeting with FDA Scheduled for Q3 2021 CHATHAM, N.J., June 21, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) as a potential treatment for Long COVID Syndrome (Long COVID) which is now known officially as Post-Acute Sequelae of COVID-19 (PASC1). Tonix plans to meet with the U.S. Food and Drug Administration (FDA) in the third quarter of 2021 to seek agreement on the design...

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

Written by Customer Service on June 21, 2021. Posted in Public Companies.

Picture 1Phase 2: Improvement in All Key DomainsPicture 2Favorable Efficacy Already at Low ANAVEX®2-73 DosesPicture 3Rett Syndrome Behaviour Questionnaire (RSBQ) Total ScorePicture 4RSBQ Subscale ScoresPicture 5ADAMS Total ScorePicture 6ADAMS Subscale ScoresANAVEX®2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints RSBQ (p = 0.035) and CGI-I (p = 0.029) Data strengthens milestone to advance regulatory approval pathway for adult patients with Rett syndrome and continued development in other autism spectrum disorders NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex”...

Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy

Written by Customer Service on June 21, 2021. Posted in Public Companies.

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced enrollment of the first subject in the OLYMPIA Phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new treatment option for patients with Stage 1 Neurotrophic Keratopathy,” said Jeffrey Nau, Ph.D., MMS, president and chief executive officer of Oyster Point Pharma. “We believe that NK affects more patients than are currently diagnosed as the disease has the potential to be undiagnosed or misdiagnosed. Stage 1 NK patients may...

Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

Written by Customer Service on June 21, 2021. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European Commission has granted orphan designation for the Company’s lead product candidate, DAY101, for the treatment of glioma. The designation was based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products. DAY101 is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway. Day One is conducting a pivotal Phase 2 clinical trial (FIREFLY-1) of DAY101 in pediatric, adolescent and young adult patients with recurrent or progressive...

MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

Written by Customer Service on June 21, 2021. Posted in Public Companies.

MediPharm Labs’ Cannabis Drug Licence and expertise qualifies and positions the Company to supply clinical trial material, assist in investigation protocol and provide regulatory support for multiple trialsThree initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.BARRIE, Ontario, June 21, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality development and manufacturing of cannabis API and derivative products, is pleased to announce it has entered into a research partnership Master Agreement (the “Agreement”) with McMaster University....

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

Written by Customer Service on June 21, 2021. Posted in Public Companies.

– Fulcrum to host conference call on June 24, 2021 at 8:00am ET to present results from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) – CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 28th Annual FSHD Society International Research Congress (IRC). June 24, 2021 IRC Virtual Presentations10:43 am ET – Use of snRNA-seq to characterize the skeletal muscle microenvironment during pathogenesis in FSHD 1:33 pm ET – A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with...

Devon Energy Establishes New Environmental Performance Targets Including Net Zero GHG Emissions

Written by Customer Service on June 21, 2021. Posted in Public Companies.

KEY TARGET HIGHLIGHTSAchieve net zero greenhouse gas (GHG) emissions for Scopes 1 and 2 by 2050 Reduce Scopes 1 and 2 GHG emissions intensity by 50% by 2030 Reduce methane emissions intensity by 65% by 2030 Achieve flaring intensity of 0.5% or lower by 2025 and eliminate routine flaring by 2030 Continue to advance water recycling rate and to use 90% or more non-freshwater for completions activities in the most active operating areas within the Delaware Basin Engage value chain in assessment of performance in key environmental, social, and governance (ESG) areasOKLAHOMA CITY, June 21, 2021 (GLOBE NEWSWIRE) — Devon Energy Corp. (NYSE: DVN) announced today it is establishing new environmental performance targets focused on reducing the carbon intensity of its operations, minimizing freshwater use, and engaging constructively with...

Everything Blockchain Acquires Energy Technology Business

Written by Customer Service on June 21, 2021. Posted in Mergers And Acquisitions.

Cedric Harris Named Chief Research Officer Fleming Island, Florida, June 21, 2021 (GLOBE NEWSWIRE) — Everything Blockchain, Inc., (OTCMKTS: OBTX), an advanced software development and services company specializing in blockchain technologies and decentralized processing, announced today that it has acquired 100% of the outstanding shares of 832 Energy Technology Consultants, with its base of operations in Houston, Texas at its current valuation of $1.5 million. This is the second acquisition Everything Blockchain has made in the last three months. In additional to this acquisition, the Company has entered into two additional Letters of Intent for two additional strategic acquisitions that takes the Company one step closer to providing a blockchain platform that operates between regulatory agencies and industry. 832 Energy Technology...

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Day: June 21, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals